Loading
A phase 3 trial of Tucidinostat (chidamide) and XNW5004 in peripheral T-cell lymphomas, run by Evopoint Biosciences Inc., now recruiting.
A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma is a phase 3 interventional study registered as NCT06776952 by Evopoint Biosciences Inc., with 120 participants planned, started 2025-04-10 and due to reach its primary completion in 2028-01. Interventions recorded: XNW5004 ; Chidamide placebo and XNW5004 placebo; Chidamide.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Tucidinostat (chidamide), Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Shares Evopoint Biosciences and the tag pipeline.
Shares Tucidinostat (chidamide), Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Shares Evopoint Biosciences and the tag pipeline.
Shares Evopoint Biosciences and the tag pipeline.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/